Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors

NCT03621982 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.

NCT NCT03621982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03621982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Lead sponsor
ADC Therapeutics S.A.
Phase
Phase 1
Overall status
Terminated
Start date
November 9, 2018
Completion date
December 14, 2022
Enrollment
78 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colo-rectal cancer, esophageal cancer, fallopian tube cancer, gastric cancer, head and neck cancer squamous cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, pancreas cancer, renal cell carcinoma, triple-negative breast cancer